Prs16 - Modeled Survival Gains of Patients With Cystic Fibrosis (Cf) Aged ≥12 Years Heterozygous for F508del-CFTR and a Residual Function Mutation (F508del/Rf) Treated With the Cf Transmembrane Conductance Regulator Modulator (Cftrm) Tezacaftor/Ivacaftor (Tez/Iva)
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2410
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV